SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against BioAge Labs, Inc. due to alleged violations of federal securities laws related to misleading information about its STRIDES Phase 2 clinical trial [2][4]. Group 1: Company Overview - BioAge Labs, Inc. (NASDAQ: BIOA) completed its initial public offering on September 27, 2024, selling 12.65 million shares at $18 per share, including an additional 1.65 million shares purchased by underwriters [4]. - The company announced the discontinuation of its STRIDES Phase 2 study for the investigational drug candidate azelaprag on December 6, 2024, after liver transaminitis was observed in some subjects [5]. Group 2: Stock Performance - Following the announcement of the discontinuation of the STRIDES Phase 2 study, BioAge's stock price plummeted from$20.09 per share on December 6, 2024, to $4.65 per share on December 7, 2024 [6]. Group 3: Legal Proceedings - A federal securities class action has been filed against BioAge, with a deadline of March 10, 2025, for investors to seek the role of lead plaintiff [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [7].